-- 根据4月24日提交给交易所的文件，迈宝生物（上海）有限公司（港交所代码：2493，上海证券交易所代码：688062）已将其香港上市发行价定为每股27.64港元。 这家总部位于中国的制药公司预计将于周一公布配股结果。 股票将于周二开始交易，每手200股。
Related Articles
Asia
Dongjiang Environmental's Loss Widens 2.7% in Q1
Dongjiang Environmental (HKG:0895, SHE:002672) recorded an attributable loss of 150.2 million yuan in the first quarter of 2026, 2.7% wider than 146.3 million yuan a year prior, according to a Monday Hong Kong bourse filing.Loss per share widened to 0.14 yuan from 0.13 yuan in the corresponding period of the previous fiscal year.The waste disposal management company's revenue from operations declined 13% to 602.6 million yuan from 695.9 million yuan in the year-ago period.
$HKG:0895$SHE:002672
Sectors
Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday
Health care stocks were edging higher pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2% and the iShares Biotechnology ETF (IBB) marginally advancing.Organon (OGN) has agreed to be acquired by Sun Pharmaceutical Industries for $14 per share in an all-cash deal with an $11.75 billion enterprise valuation, the companies said. Shares of Organon were up more than 17% premarket.Oruka Therapeutics (ORKA) stock was up more than 34% after the company said 63.5% of patients treated with ORKA-001 achieved the primary endpoint of complete skin clearance at week 16 in a phase 2a trial in moderate-to-severe plaque psoriasis.Ligand Pharmaceuticals (LGND) shares were up more than 3% after the company said it has agreed to purchase biotechnology peer Xoma Royalty (XOMA) in an all-cash deal valued at roughly $739 million.
$IBB$LGND$OGN$ORKA$XLV$XOMA
Asia
Zuoli Kechuang Logs Drop in Q1 Profit
Zuoli Kechuang Micro-finance Company (HKG:6866) recorded a decline in attributable profit in the first quarter of 2026 to 13.6 million yuan from 14.8 million yuan a year prior, according to a Monday Hong Kong bourse filing.Net interest income for the three months slipped to 28.4 million yuan from 35.2 million yuan in the year-ago period.
$HKG:6866